Fibrin-Specific Thrombolysis with Tissue-Type Plasminogen Activator and Single Chain Urokinase-Type Plasminogen Activator

  • D. Collen
Conference paper
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 1)


Mammalian blood contains an enzymatic system capable of dissolving blood clots, which is called the fibrinolytic enzyme system. The fibrinolytic system comprises a proenzyme, plasminogen, which can be converted to the active enzyme plasmin, which will degrade fibrin. Plasminogen activation is mediated by plasminogen activators which are classified as either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Inhibition of the fibrinolytic system may occur at the level of the activators or at the level of generated plasmin [1].


Plasminogen Activator Fibrin Clot Fibrinolytic System Plasminogen Activation Catalytic Rate Constant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Cohen D (1980) On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 43: 77–89Google Scholar
  2. 2.
    Wiman B, Collen D (1978) Molecular mechanism of physiological fibrinolysis. Nature 272: 549–550PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen D (1986) Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA). Potential for fibrin-specific thrombolytic therapy. Progress in Haemostasis 8:(in press)Google Scholar
  4. 4.
    Collen D (1985) Human tissue-type plasminogen activator: from the laboratory to the bedside. Circulation 72: 18–20PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • D. Collen

There are no affiliations available

Personalised recommendations